Abstract Details

Title Improvement in Quality of Life and Functional Status Following Valbenazine Treatment in Patients with Tardive Dyskinesia: Real-world Data from a Chart Extraction and Clinician Survey

Topic Movement Disorders

Presentation(s) P10 - Poster Session 10 (5:00 PM-6:00 PM)

Poster/Presentation
Number 5-019

Objective To update and expand upon a previously completed survey and chart extraction by capturing more recent information on tardive dyskinesia (TD) burden and clinician-reported improvement with treatment across various areas, including physical, functional, social, emotional, and independence.

Background TD significantly impacts quality of life (QoL) beyond movement symptoms. A web-based survey and chart extraction among US physicians, nurse practitioners, and physician assistants characterized TD burden and improvement following valbenazine treatment.

Design/Methods Clinicians reported data from patient charts who started valbenazine treatment between 1/1/2024 and 6/30/2024 and completed ≥2 months of valbenazine treatment with ≥1 follow-up visit.

Results

Interim analyses included responses from 78 clinicians caring for 164 patients taking valbenazine. Mean patient age was 51.2 (standard deviation: 13.4) years, 57.9% were female. The most common underlying psychiatric diagnoses were schizophrenia (42.1%), bipolar disorder (34.1%), major depressive disorder (25.0%), and schizoaffective disorder (17.7%).

Most patients (82.9%) had mild-to-moderate TD severity; 12.2% had severe TD. At the survey time, nearly all patients (93.9%) had experienced TD improvement after initiating valbenazine; of those patients (n=154), 87.7% experienced improvement within 4 weeks.

TD had an impact on functional ability in 95.1% of patients. The most commonly impacted areas of function were emotionality, socialization, activities of daily living (ADLs), and mouth/throat function. Among those impacted (n=156), 94.2% improved in overall functional status.

Additionally, 87.8% of all patients experienced improvement in independence. For those with available information on antipsychotic adherence (n=115), over half (52.2%) experienced improved adherence.

Conclusions Real-world, valbenazine-treated TD patients experienced improvement in functional, social, independence, emotional, and physical aspects of their lives, irrespective of TD severity. Data on independence, ADLs, and antipsychotic medication adherence added new information to prior analyses in functional and QoL improvements beyond movement symptoms.

Authors/Disclosures
Michael Serbin (Neurocrine Biosciences) PRESENTER	Michael Serbin has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc. Michael Serbin has stock in Neurocrine Biosciences, Inc.
Rimal Bera (University of California, Irvine School of Medicine)	Dr. Bera has nothing to disclose.
Justin Nedzesky, PharmD, MS	Dr. Nedzesky has received personal compensation for serving as an employee of Neurocrine Biosciences. Dr. Nedzesky has stock in Neurocrine Biosciences.
Ivan Gandayuwana	Mr. Gandayuwana has nothing to disclose.
Dan Winkelman	Mr. Winkelman has received personal compensation for serving as an employee of IQVIA.
Dawn Vanderhoef	Dr. Vanderhoef has received personal compensation for serving as an employee of Neurocrine Biosciences Inc. Dr. Vanderhoef has stock in Neurocrine Biosciences, Inc.
Morgan Bron	Morgan Bron has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.. Morgan Bron has or had stock in Neurocrine.

��ɫ��

��ɫ��